Issue

Vol. 63 No. 9: Issue 9

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Optimizing expression of antiviral cyanovirin-N homology gene using response surface methodology and protein structure prediction

https://doi.org/10.14715/cmb/2017.63.9.17
H. Lotfi
Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
M. A. Hejazi
Department of Genomics, Branch for the Northwest and West Region, Agricultural Biotechnology Research Institute of Iran (ABRII), Agriculture research, Education and Extension Organization (AREEO), Tabriz, Iran
M. K. Heshmati
Department of Food Science and Technology, Faculty of Agriculture, University of Tabriz, Iran
S. A. Mohammadi
Department of Medical Biotechnology, Faculty of Advanced Medical Science, Tabriz University of Medical Sciences, Tabriz, Iran
N. Zarghami
Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Corresponding Author(s) : N. Zarghami

zarghami@tbzmed.ac.ir

Cellular and Molecular Biology, Vol. 63 No. 9: Issue 9

Abstract

Cyanovirin-N (CVN) is well known as an anti-HIV protein. The efficient production of low cost microbicides for preventing the HIV-infection  has lately become a requirement worldwide. The aim of the present study was to optimize the expression of antiviral Cyanovirin-N homology gene found in the indigenous strain of Nostoc ellipsospourum LZN using Response Surface Methodology (RSM) and Protein Structure Analysis. Optimization of three induction factors (IPTG concentration (0.1, 0.55 and 1mM), temperature for bacterial growth (20, 28.5 and 37°C) and induction time (4, 10 and 16h) was done using RSM and Box-Behnken Design. Total RNA extraction was performed and mRNA levels were quantified in each experimental design by one-step SYBR qPCR. Protein structure was predicted using I-TASSER server. The full-length sequence of LZN-CVN gene is 306 bp in length, due mostly to five mutations. RSM analysis showed that the optimum condition to obtain maximum fold change was a concentration of 0.6mM IPTG, temperature set to 29°C and a 12h long induction time. The extracted protein from periplasmic fraction (8 kDa) was verified via SDS-PAGE. The high percentage of LZN-CVN similarity was demonstrated with PDB (Protein Data Bank) accession code of 2rp3A (CVN domain B mutant) and the ligand binding sites were related to N42, V43, D44, G45, S52, N53 and E56 residues. Different expression systems could assist in the development of anti-HIV proteins in a large scale. The LZN-CVN protein was successfully expressed in the E.coli system. RSM could be applied to a series of mathematical and statistical methods for modeling and analysis of responses which are influenced by various variables of interest.

Keywords

Antiviral Cyanovirin-N Gene expression Nostoc ellipsospourum Response Surface Methodology Sequencing.
Lotfi, H., Hejazi, M. A., Heshmati, M. K., Mohammadi, S. A., & Zarghami, N. (2017). Optimizing expression of antiviral cyanovirin-N homology gene using response surface methodology and protein structure prediction. Cellular and Molecular Biology, 63(9), 96–105. https://doi.org/10.14715/cmb/2017.63.9.17
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Gustafson KR, Sowder RC, 2nd, Henderson LE, Cardellina JH, 2nd, McMahon JB, Rajamani U, et al. Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the cyanobacterium Nostoc ellipsosporum. Biochemical and biophysical research communications. 1997 ;238:223-8.
  2. Barrientos LG, O'Keefe BR, Bray M, Sanchez A, Gronenborn AM, Boyd MR. Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. Antiviral research. 2003 ;58:47-56.
  3. O'Keefe BR, Smee DF, Turpin JA, Saucedo CJ, Gustafson KR, Mori T, et al. Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrobial agents and chemotherapy. 2003 ;47:2518-25.
  4. Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, Mori T, et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrobial agents and chemotherapy. 1997 ;41:1521-30.
  5. Dey B, Lerner DL, Lusso P, Boyd MR, Elder JH, Berger EA. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. Journal of virology. 2000 ;74:4562-9.
  6. Buffa V, Stieh D, Mamhood N, Hu Q, Fletcher P, Shattock RJ. Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. The Journal of general virology. 2009 ;90:234-43.
  7. Balzarini J, Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet (London, England). 2007 ;369:787-97.
  8. Helle F, Wychowski C, Vu-Dac N, Gustafson KR, Voisset C, Dubuisson J. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. The Journal of biological chemistry. 2006 ;281:25177-83.
  9. Barrientos LG, Matei E, Lasala F, Delgado R, Gronenborn AM. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition. Protein engineering, design & selection : PEDS. 2006 ;19:525-35.
  10. Mori T, Boyd MR. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Antimicrob Agents Chemother. 2001 ;45:664-72.
  11. Fischetti L, Barry SM, Hope TJ, Shattock RJ. HIV-1 infection of human penile explant tissue and protection by candidate microbicides. AIDS (London, England). 2009;23:319.
  12. Boes A, Reimann A, Twyman RM, Fischer R, Schillberg S, Spiegel H. A Plant-Based Transient Expression System for the Rapid Production of Malaria Vaccine Candidates. Vaccine Design: Methods and Protocols, Volume 2: Vaccines for Veterinary Diseases. 2016:597-619.
  13. Sullivan CJ, Pendleton ED, Sasmor HH, Hicks WL, Farnum JB, Muto M, et al. A cell"free expression and purification process for rapid production of protein biologics. Biotechnology journal. 2016;11:238-48.
  14. Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, Mori T, et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrobial agents and chemotherapy. 1997;41:1521-30.
  15. Colleluori DM, Tien D, Kang F, Pagliei T, Kuss R, McCormick T, et al. Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development. Protein expression and purification. 2005;39:229-36.
  16. Gao X, Chen W, Guo C, Qian C, Liu G, Ge F, et al. Soluble cytoplasmic expression, rapid purification, and characterization of cyanovirin-N as a His-SUMO fusion. Applied microbiology and biotechnology. 2010;85:1051-60.
  17. Giomarelli B, Provvedi R, Meacci F, Maggi T, Medaglini D, Pozzi G, et al. The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1. Aids. 2002;16:1351-6.
  18. Liu X, Lagenaur LA, Simpson DA, Essenmacher KP, Frazier-Parker CL, Liu Y, et al. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrobial agents and chemotherapy. 2006;50:3250-9.
  19. Ndesendo VM, Pillay V, Choonara YE, Buchmann E, Bayever DN, Meyer LC. A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections. aaps Pharmscitech. 2008;9:505-20.
  20. Mori T, Barrientos LG, Han Z, Gronenborn AM, Turpin JA, Boyd MR. Functional homologs of cyanovirin-N amenable to mass production in prokaryotic and eukaryotic hosts. Protein expression and purification. 2002;26:42-9.
  21. Colgan R, Atkinson CJ, Paul M, Hassan S, Drake PM, Sexton AL, et al. Optimisation of contained Nicotiana tabacum cultivation for the production of recombinant protein pharmaceuticals. Transgenic research. 2010;19:241-56.
  22. Drake PM, Barbi T, Sexton A, McGowan E, Stadlmann J, Navarre C, et al. Development of rhizosecretion as a production system for recombinant proteins from hydroponic cultivated tobacco. The FASEB Journal. 2009;23:3581-9.
  23. Drake PM, de Moraes Madeira L, Szeto TH, Ma JK. Transformation of Althaea officinalis L. by Agrobacterium rhizogenes for the production of transgenic roots expressing the anti-HIV microbicide cyanovirin-N. Transgenic research. 2013;22:1225-9.
  24. O'Keefe BR, Murad AM, Vianna GR, Ramessar K, Saucedo CJ, Wilson J, et al. Engineering soya bean seeds as a scalable platform to produce cyanovirin"N, a non"ARV microbicide against HIV. Plant biotechnology journal. 2015;13:884-92.
  25. Vamvaka E, Evans A, Ramessar K, Krumpe L, Shattock R, O'Keefe B, et al. Cyanovirin-N produced in rice endosperm offers effective pre-exposure prophylaxis against HIV-1BaL infection in vitro. Plant cell reports. 2016;35:1309-19.
  26. Bewley CA, Gustafson KR, Boyd MR, Covell DG, Bax A, Clore GM, et al. Solution structure of cyanovirin-N, a potent HIV-inactivating protein. Nature Structural & Molecular Biology. 1998;5:571-8.
  27. Zhang Y, Wei X, Lu Z, Pan Z, Gou X, Venkitasamy C, et al. Optimization of culturing conditions of recombined Escherichia coli to produce umami octopeptide-containing protein. Food Chemistry. 2017;227:78-84.
  28. Patil MD, Shinde KD, Patel G, Chisti Y, Banerjee UC. Use of response surface method for maximizing the production of arginine deiminase by Pseudomonas putida. Biotechnology Reports. 2016;10:29-37.
  29. Mohajeri A, Pilehvar-Soltanahmadi Y, Abdolalizadeh J, Karimi P, Zarghami N. Effect of Culture Condition Variables on Human Endostatin Gene Expression in Escherichia coli Using Response Surface Methodology. Jundishapur Journal of Microbiology. 2016;9.
  30. Li R-F, Wang B, Liu S, Chen S-H, Yu G-H, Yang S-Y, et al. Optimization of the Expression Conditions of CGA-N46 in Bacillus subtilis DB1342 (p-3N46) by Response Surface Methodology. Interdisciplinary Sciences: Computational Life Sciences. 2016;8:277-83.
  31. Bhattacharjee K, Joshi SR. A selective medium for recovery and enumeration of endolithic bacteria. Journal of Microbiological Methods. 2016;129:44-54.
  32. Su Y, Wang T, Yang W, Huang C, Fan G. DNA extraction and RAPD analysis of Podocarpus. Acta Scientiarum Naturalium Universitatis Sunyatseni. 1997;37:11-8.
  33. French C, Keshavarz-Moore E, Ward JM. Development of a simple method for the recovery of recombinant proteins from the Escherichia coli periplasm. Enzyme and Microbial Technology. 1996 ;19:332-8.
  34. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 ;227:680-5.
  35. Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. The I-TASSER Suite: protein structure and function prediction. Nature methods. 2015 ;12:7-8.
  36. Wu S, Zhang Y. LOMETS: a local meta-threading-server for protein structure prediction. Nucleic acids research. 2007;35:3375-82.
  37. Matei E, Furey W, Gronenborn AM. Solution and crystal structures of a sugar binding site mutant of cyanovirin-N: no evidence of domain swapping. Structure (London, England : 1993). 2008;16:1183-94.
  38. Barrientos LG, Louis JM, Ratner DM, Seeberger PH, Gronenborn AM. Solution structure of a circular-permuted variant of the potent HIV-inactivating protein cyanovirin-N: structural basis for protein stability and oligosaccharide interaction. Journal of molecular biology. 2003 ;325:211-23.
  39. Fromme R, Katiliene Z, Giomarelli B, Bogani F, Mc Mahon J, Mori T, et al. A monovalent mutant of cyanovirin-N provides insight into the role of multiple interactions with gp120 for antiviral activity. Biochemistry. 2007;46:9199-207.
  40. Matei E, Zheng A, Furey W, Rose J, Aiken C, Gronenborn AM. Anti-HIV activity of defective cyanovirin-N mutants is restored by dimerization. The Journal of biological chemistry. 2010 ;285:13057-65.
  41. Matei E, Louis JM, Jee J, Gronenborn AM. NMR solution structure of a cyanovirin homolog from wheat head blight fungus. Proteins. 2011;79:1538-49.
  42. Matei E, Basu R, Furey W, Shi J, Calnan C, Aiken C, et al. Structure and Glycan Binding of a New Cyanovirin-N Homolog. The Journal of biological chemistry. 2016 .
  43. Koharudin LM, Viscomi AR, Montanini B, Kershaw MJ, Talbot NJ, Ottonello S, et al. Structure-function analysis of a CVNH-LysM lectin expressed during plant infection by the rice blast fungus Magnaporthe oryzae. Structure (London, England : 1993). 2011;19:662-74.
  44. Koharudin LM, Viscomi AR, Jee JG, Ottonello S, Gronenborn AM. The evolutionarily conserved family of cyanovirin-N homologs: structures and carbohydrate specificity. Structure (London, England : 1993). 2008 ;16:570-84.
  45. Shahzad-ul-Hussan S, Gustchina E, Ghirlando R, Clore GM, Bewley CA. Solution structure of the monovalent lectin microvirin in complex with Man(alpha)(1-2)Man provides a basis for anti-HIV activity with low toxicity. The Journal of biological chemistry. 2011 10;286:20788-96.
  46. Koharudin LM, Furey W, Gronenborn AM. A designed chimeric cyanovirin-N homolog lectin: structure and molecular basis of sucrose binding. Proteins. 2009 ;77:904-15.
  47. Choi JH, Keum KC, Lee SY. Production of recombinant proteins by high cell density culture of Escherichia coli. Chemical Engineering Science. 2006;61:876-85.
  48. Makrides SC. Strategies for achieving high-level expression of genes in Escherichia coli. Microbiological Reviews. 1996;60:512-38.
  49. Choi JH, Lee SY. Secretory and extracellular production of recombinant proteins using Escherichia coli. Appl Microbiol Biotechnol. 2004 ;64:625-35.
  50. Jeong KJ, Lee SY. Excretion of Human β-Endorphin into Culture Medium by Using Outer Membrane Protein F as a Fusion Partner in Recombinant Escherichia coli. Applied and Environmental Microbiology. 2002;68:4979-85.
  51. Bewley CA. Solution structure of a cyanovirin-N:Man alpha 1-2Man alpha complex: structural basis for high-affinity carbohydrate-mediated binding to gp120. Structure (London, England : 1993). 2001 ;9:931-40.
  52. Colleluori DM, Tien D, Kang F, Pagliei T, Kuss R, McCormick T, et al. Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development. Protein Expr Purif. 2005 ;39:229-36.
  53. Gao X, Chen W, Guo C, Qian C, Liu G, Ge F, et al. Soluble cytoplasmic expression, rapid purification, and characterization of cyanovirin-N as a His-SUMO fusion. Appl Microbiol Biotechnol. 2010 ;85:1051-60.
  54. Barrientos LG, Louis JM, Botos I, Mori T, Han Z, O'Keefe BR, et al. The domain-swapped dimer of cyanovirin-N is in a metastable folded state: reconciliation of X-ray and NMR structures. Structure (London, England : 1993). 2002;10:673-86.
  55. Correa A, Oppezzo P. Tuning different expression parameters to achieve soluble recombinant proteins in E. coli: advantages of high-throughput screening. Biotechnol J. 2011;6:715-30.
  56. Cao W, Li H, Zhang J, Li D, Acheampong DO, Chen Z, et al. Periplasmic expression optimization of VEGFR2 D3 adopting response surface methodology: antiangiogenic activity study. Protein Expr Purif. 2013 ;90:55-66.
  57. Collins T, Azevedo-Silva J, da Costa A, Branca F, Machado R, Casal M. Batch production of a silk-elastin-like protein in E. coli BL21(DE3): key parameters for optimisation. Microbial cell factories. 2013 Feb 27;12:21.
  58. Papaneophytou CP, Rinotas V, Douni E, Kontopidis G. A statistical approach for optimization of RANKL overexpression in Escherichia coli: purification and characterization of the protein. Protein Expr Purif. 2013 ;90:9-19.
  59. Gunst RF. Response surface methodology: process and product optimization using designed experiments. Taylor & Francis Group; 1996.
  60. Gholami Tilko P, Hajihassan Z, Moghimi H. Optimization of recombinant β-NGF expression in Escherichia coli using response surface methodology. Preparative Biochemistry and Biotechnology. 2016:1-8.
  61. Larentis AL, Argondizzo AP, Esteves Gdos S, Jessouron E, Galler R, Medeiros MA. Cloning and optimization of induction conditions for mature PsaA (pneumococcal surface adhesin A) expression in Escherichia coli and recombinant protein stability during long-term storage. Protein Expr Purif. 2011 Jul;78:38-47.
  62. Sun J, Su Y, Wang T. Expression, purification and identification of CtCVNH, a novel anti-HIV (Human Immunodeficiency Virus) protein from Ceratopteris thalictroides. International journal of molecular sciences. 2013;14:7506-14.
  63. Koharudin LMI, Viscomi AR, Jee J-G, Ottonello S, Gronenborn AM. The Evolutionarily Conserved Family of Cyanovirin-N Homologs: Structures and Carbohydrate Specificity. Structure (London, England : 1993). 2008;16:570-84.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 848 Download : 397